MYB and breast carcinoma: Our findings identify a novel role for p95HER2-specific miRNA changes in distinguishing p95HER2 positive cancers from those overexpressing only HER2, and uncover a signaling axis from miR-221/222 and -503 over MYB proteins to TIMP2 important for controlling cell motility in breast cancer.